ADVM Research and Charts

ADVM - Adverum Biotechnologies Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-04-03)

Last 3.94	Change ⇓ -0.32 (-7.51%)	Volume 151,801
	Open 4.01	High 4.12	Low 3.77

8EMA (Daily) 4.39	40EMA (Daily) 4.61	50EMA (Daily) 4.67	STO (Daily) 15.208	MACD Hist (Daily) -0.261
8EMA (Weekly) 4.570	40EMA (Weekly) 5.46	50EMA (Weekly) 5.45	STO (Weekly) 47.148	MACD Hist (Weekly) 0.030


Company Profile
Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.